The anti-breast cancer drugs such as Vemurafenib, Ponatinib, Crizotinib, Dacomitinib, Regorafenib, Pazopanib, Neratinib, Midostaurin, Nintedanib, Bosutinib, Sunitinib, Vandetanib, Dasatinib, Sorafenib, Lapatinib, Everolimus, Erlotinib, Temsirolimus, Gefitinib, Imatinib, and Rapamycin showed interactions with the genes EGFR and ERBB2. The gene discussed is EGFR; the disease is breast cancer.